Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central nervous system toxicity with high-dose Ara-C.

T L Hwang, W K Yung, E H Estey

    Neurology
    |October 1, 1985
    PubMed
    Summary

    High-dose cytarabine (Ara-C) therapy can cause central nervous system (CNS) complications in acute leukemia patients. However, these neurological side effects are often reversible with careful monitoring and dose management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Success rate of induction of labour in twin pregnancies relative to singleton pregnancies in a predominantly Chinese population.

    Hong Kong medical journal = Xianggang yi xue za zhi·2025
    Same author

    Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

    Leukemia·2017
    Same author

    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

    Leukemia·2017
    Same author

    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

    Leukemia·2016
    Same author

    Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

    Leukemia·2016
    Same author

    Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

    Leukemia·2016

    Area of Science:

    • Neuro-oncology
    • Hematology
    • Clinical Pharmacology

    Background:

    • High-dose cytarabine (Ara-C) is a cornerstone in treating acute leukemia.
    • Central nervous system (CNS) toxicity is a known complication of chemotherapy.
    • Understanding the incidence and characteristics of CNS complications from high-dose Ara-C is crucial for patient management.

    Purpose of the Study:

    • To evaluate the incidence and nature of CNS complications in adult acute leukemia patients treated with intravenous (IV) high-dose Ara-C.
    • To identify risk factors associated with these neurological adverse events.
    • To assess the reversibility and clinical outcomes of CNS complications.

    Main Methods:

    • Retrospective analysis of 118 adult acute leukemia patients receiving IV high-dose Ara-C.

    Related Experiment Videos

  • Detailed review of neurological symptoms, timing of onset, and cumulative dosage.
  • Assessment of symptom resolution and treatment modifications.

    • Main Results:

    • Fourteen patients (12%) experienced CNS complications, including cerebellar signs, encephalopathy, seizures, or leukoencephalopathy.
    • Symptoms typically manifested within 24 hours post-treatment.
    • Higher cumulative doses (> 24 g/m2) correlated with more severe or irreversible symptoms.
    • Lower cumulative doses often allowed for symptom resolution despite continued therapy.

    Conclusions:

    • CNS complications from high-dose Ara-C are an acceptable risk in acute leukemia treatment.
    • Early recognition and dose adjustment can lead to reversible neurological outcomes.
    • Careful monitoring and adherence to treatment protocols are essential to mitigate these risks.